Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -32.14% is 23% above its 5-year average of -41.51%, near the high end of its 5-year range (-48.97%–-29.05%).
As of the fiscal period ended Tuesday, June 30, 2026. 26.67% above its 12-month average of -43.83%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -32.14%.
RETURN ON EQUITY (ROE)
-32.14%
RETURN ON EQUITY (ROE) AVG TTM
-43.83%
RETURN ON EQUITY (ROE) AVG 3Y
-44.93%
RETURN ON EQUITY (ROE) AVG 5Y
-41.51%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+26.67%
CURRENT VS 3Y AVG
+28.47%
CURRENT VS 5Y AVG
+22.58%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+23.50%
vs the sector median at left
Relay Therapeutics, Inc.
Market Cap
$4.02B
Return on Equity (ROE)
-32.14%
TTM Avg
-43.83%
3Y Avg
-44.93%
5Y Avg
-41.51%
Market Cap
$4.05B
Return on Equity (ROE)
-18.38%
TTM Avg
-15.28%
3Y Avg
-7.60%
5Y Avg
-0.19%
Market Cap
$3.96B
Return on Equity (ROE)
1.40%
TTM Avg
-2.98%
3Y Avg
-2.73%
5Y Avg
0.21%
Market Cap
$4.15B
Return on Equity (ROE)
14.23%
TTM Avg
-7.71%
3Y Avg
-5.30%
5Y Avg
-10.52%
Market Cap
$3.85B
Return on Equity (ROE)
-73.75%
TTM Avg
-63.05%
3Y Avg
-54.60%
5Y Avg
-25.68%
Market Cap
$4.28B
Return on Equity (ROE)
-44.02%
TTM Avg
-30.64%
3Y Avg
-28.05%
5Y Avg
-12.80%
Market Cap
$4.40B
Return on Equity (ROE)
-44.68%
TTM Avg
-52.94%
3Y Avg
-55.51%
5Y Avg
-46.01%
Market Cap
$4.42B
Return on Equity (ROE)
-42.32%
TTM Avg
-13.82%
3Y Avg
-5.11%
5Y Avg
-5.11%
Market Cap
$4.43B
Return on Equity (ROE)
N/A
TTM Avg
-107.43%
3Y Avg
-58.28%
5Y Avg
-52.10%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relay Therapeutics, Inc. (RLAY) | $4.02B | -32.14% | -43.83% | -44.93% | -41.51% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.05B | -18.38% | -15.28% | -7.60% | -0.19% |
| ICU Medical, Inc. (ICUI)vs › | $3.96B | 1.40% | -2.98% | -2.73% | 0.21% |
| LivaNova PLC (LIVN)vs › | $4.15B | 14.23% | -7.71% | -5.30% | -10.52% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.85B | -73.75% | -63.05% | -54.60% | -25.68% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.28B | -44.02% | -30.64% | -28.05% | -12.80% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.40B | -44.68% | -52.94% | -55.51% | -46.01% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.42B | -42.32% | -13.82% | -5.11% | -5.11% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.43B | N/A | -107.43% | -58.28% | -52.10% |
| Veracyte, Inc. (VCYT)vs › | $3.57B | 8.25% | 3.56% | -0.85% | -3.10% |
ROE
-32.1%
ROA
-29.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -32.14% |
| 2026-03-31 | -42.47% |
| 2025-12-31 | -48.76% |
| 2025-09-30 | -48.97% |
| 2025-06-30 | -46.80% |
| 2025-03-31 | -46.23% |
| 2024-12-31 | -43.42% |
| 2024-09-30 | -41.15% |
| 2024-06-30 | -47.35% |
| 2024-03-31 | -44.13% |
| 2023-12-31 | -45.47% |
| 2023-09-30 | -41.88% |
| 2023-06-30 | -42.51% |
| 2023-03-31 | -36.53% |
| 2022-12-31 | -30.57% |
| 2022-09-30 | -29.05% |
| 2022-06-30 | -34.26% |
| 2022-03-31 | -45.58% |
| 2021-12-31 | -40.53% |
| 2021-09-30 | -45.73% |
| 2021-06-30 | -38.22% |
| 2021-03-31 | -9.51% |
| 2020-12-31 | -6.87% |
| 2020-09-30 | -15.64% |
| 2020-03-31 | -25.64% |
